Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
NCT ID: NCT04081389
Last Updated: 2023-09-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
9 participants
INTERVENTIONAL
2019-12-06
2023-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
NCT05846789
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
NCT04059003
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00003953
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
NCT01238133
Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer
NCT00135018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To examine the safety and tolerability profile of the combination of rintatolimod celecoxib +/- interferon alpha-2b, when given as CKM along with chemotherapy in the neoadjuvant setting in early stage triple negative breast cancer.
II To identify the appropriate dose level of CKM and paclitaxel for future clinical exploration.
SECONDARY OBJECTIVES:
II. • Evaluate the effect of neoadjuvant CKM + paclitaxel on pathological response and breast MRI response in early stage triple negative breast cancer patients.
III. • Evaluate the overall and recurrence-free survival in early stage triple negative breast cancer patients that received neoadjuvant CKM + paclitaxel.
EXPLORATORY OBJECTIVES:
I• To evaluate longitudinal changes of blood biomarkers such as peripheral T-cell subsets, myeloid derived suppressor cells (MDSC), expression of chemokine and other immune genes, circulating immune mediators and correlate them with the clinical course post surgery.
II• Comparison of response assessment criteria for a prospective analysis using RECIST 1.1. and irRECIST
* Evaluate changes in the intratumoral levels of biomarkers, such as, peripheral T-cell subsets, myeloid derived suppressor cells (MDSC), chemokines, and immune-regulatory factors (pre- vs post-CKM + paclitaxel treatment).
OUTLINE: This is a phase Ib, dose-escalation study of recombinant interferon alfa-2b.
Patients receive celecoxib orally (PO) twice daily (BID), recombinant interferon alfa-2b intravenously (IV) over 20 minutes (omitted in lowest dose level), and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
. After completion of study treatment, patients are followed up at 2 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CKM weeks 1-3, doxorubicin, cyclophosphamide)
Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
Celecoxib
Given PO
Cyclophosphamide
Given IV
Doxorubicin
Given IV
Doxorubicin Hydrochloride
Given IV
Paclitaxel
Given IV
Recombinant Interferon Alfa-2b
Given IV
Rintatolimod
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib
Given PO
Cyclophosphamide
Given IV
Doxorubicin
Given IV
Doxorubicin Hydrochloride
Given IV
Paclitaxel
Given IV
Recombinant Interferon Alfa-2b
Given IV
Rintatolimod
Given IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have measurable disease. Multi-centric disease is allowed. If patient has another lesion which is biopsied with ER/PR positive it will be Physician discretion for this eligibility criteria.
* Prior therapy: No prior cytotoxic regimens are allowed for this malignancy. Participants may not have had prior chemotherapy, other targeted anticancer therapies, or prior radiation therapy to the ipsilateral breast for this malignancy. Prior bis-phosphonate therapy is allowed
* Patient eligible for surgery as determined by patient's surgeon
* Patient must have a lesion that amendable to biopsy, unless inaccessible and with PI approval
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Ability to swallow and retain oral medication
* Ability to undergo magnetic resonance imaging (MRI)
* Platelets \>= 100,000/uL
* Hemoglobin \>= 9 g/dL
* Absolute neutrophil count (ANC) \>= 1500/uL
* Total bilirubin =\< institutional upper limit of normal (ULN)
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and ALT (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 X institutional upper limit of normal (ULN)
* Creatinine \< ULN OR creatinine clearance \>= 50 mL/min per Cockcroft-Gault equation for patients with creatinine levels greater than ULN
* Left ventricular ejection fraction (LVEF) \>= 55%; if LVEF is \< 55% and patient is otherwise study-eligible, the principal investigator (PI) will discuss with cardiologist if patient is eligible to receive doxorubicin and participate in study
* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
* Participants on this study will be counseled on and are willing to use adequate contraceptive methods
Exclusion Criteria
* Patients with active autoimmune disease, requiring ongoing immunosuppressive therapy or history of transplantation
* Diagnosis of invasive carcinoma within the last 3 years
* Inflammatory breast cancer will be excluded from the study
* Participants who have metallic surgical implants that are not compatible with an MRI machine are not eligible
* Pregnant or nursing female participants
* Unwilling or unable to follow protocol requirements
* Patients with known serious mood disorders. (Major depression is an exclusion. Other stable mood disorders on stable therapy for \> 6 months may be allowed after consultation with PI)
* Cardiac risk factors including:
* Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent
* Patients with a New York Heart Association classification of III or IV
* History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years
* Prior allergic reaction or hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) or any drugs administered on protocol
* Any history of allergy to sulfonamides
* Any history of autoimmune hepatitis
* Grade 1 or higher neuropathy
* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Advancing Translational Sciences (NCATS)
NIH
Roswell Park Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shipra Gandhi
Role: PRINCIPAL_INVESTIGATOR
Roswell Park Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Roswell Park Cancer Institute
Buffalo, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-05299
Identifier Type: REGISTRY
Identifier Source: secondary_id
I 73718
Identifier Type: OTHER
Identifier Source: secondary_id
I 73718
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.